Gilead Sciences reports stronger-than-expected Q1 results but projects a per-share loss for 2026, disappointing investors.
Gilead Sciences posted first-quarter earnings that surpassed analyst expectations, driven by higher product sales and cost controls. Revenue reached $6.65 billion, up 3% year-over-year, while adjusted earnings per share stood at $1.68, exceeding consensus estimates of $1.50.
Despite the positive quarter, the company revised its 2026 outlook, now projecting a loss per share due to increased R&D spending and pipeline investments. Gilead had previously guided for profitability in 2026, and the shift weighed on investor sentiment.
Shares of Gilead (GILD) dropped 4% in after-hours trading following the announcement, reflecting concerns over long-term profitability.